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Abstract 
Objective: To report the results of a pharmacist-directed blood factor stewardship program targeting 
off-label utilization designed to limit use to established organizational guidelines in high-risk 
populations.  
Methods: Prospective evaluation of recombinant factor VIIa (rFVIIa) and prothrombin complex 
concentrate (PCC) orders beginning June 2013 through May 2014 and a matched retrospective cohort 
June 2012-May 2013.  Matched cohorts were evaluated for 28-day mortality, change in INR, adverse 
events, concurrent blood product use and cost savings. 
Results: Forty-two orders for blood factor were ordered between June 2013 and May 2014, 70 orders in 
the year prior (N=112). Twenty-eight-day mortality was not different between the cohorts: 53.9% vs. 
50% (p value = 0.77).  Blood factor use with underlying liver failure and active bleeding was strongly 
associated with 28-day mortality: odds ratio, 2.9 (95% CI 1.5-7.14) and 2.91 (95% CI 0.01-2.91) 
respectively.  Blood products dispensed increased over the year with plasma products the most 
significant (1 vs. 4 p value = 0.004).  All other clinical outcomes were non-significant.  An annual cost 
savings of $375,539 was achieved, primarily through a significant reduction in rFVIIa and avoidance in 
high-risk patients. 
Conclusion:  Use of off-label blood factors can be controlled through a pharmacist-led stewardship 
program. Twenty-eight day mortality was not different between the two cohorts; however, 
identification of risk factors for death associated with blood factor use allows for restriction in high-risk 
populations, creates a discussion of futile care, and yields cost-savings. 
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Text 
Introduction 
Recombinant activated factor VII (rFVIIa, Novoseven®) is a blood factor approved for use in 
hemophilia with inhibitors; Profilnine SD®, a prothrombin complex concentrate (PCC) contains factors 
II, IX, X and is approved for hemophilia B.  Both agents are used off-label to reverse bleeding from 
vitamin K antagonism, trauma, or underlying coagulopathy.1-3  These agents are favored due to their 
small administration volume, quick onset of action, 15 minutes, and prolonged effect in vivo, between 
2.3 hours (rFVIIa) to 24 hours (Profilnine SD®).4,5   
The efficacy of blood factors in massive transfusion is equivocal. Bowles, et al reviewed all non-
hemophiliac patients who received rFVIIa for massive hemorrhage at their institution from 2003-2005.6 
Eighteen patients met these criteria; seven had underlying coagulopathy (leukemia (1), thrombotic 
thrombocytopenia purpura (1) and end stage liver disease (5)); all seven died during the admission; one 
of a myocardial infarction, the other six from multi-organ failure.  The remaining eleven patients 
suffered from trauma or surgical procedures; six survived (54%).   Eight of 18 patients received more 
than one dose of rFVIIa, including four of the seven coagulopathic patients; seven of the 8 died during 
the admission.  The authors concluded from this study that patients with underlying uncorrected 
coagulopathy and those who fail to respond to the initial dose of rFVIIa have a poorer prognosis and 
that treatment may be considered futile.   
A second study by McMillen, et al evaluated all patients with hemorrhagic shock receiving rFVIIa and 
massive transfusion support (10-12 units of packed red blood cells (pRBC) within 24 hours).7  Seventy-
two patients met these criteria; 45 died (62.5%).  Patients were stratified based on survivorship.  
Patients who died were significantly older (median age 44 vs. 32 years), had longer PT (16.4 vs 12.3) 
and higher INR (1.6 vs 1.2) at the initiation of the massive transfusion protocol.  Age, baseline PT, and 
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increased FFP administration statistically significantly increased the odds of death.   This supports the 
hypothesis that underlying coagulopathy at presentation renders blood factor use futile. 
Blood factors carry significant risks and contraindications; specifically, arterial thrombosis and 
disseminated intravascular coagulopathy (DIC).  A meta-analysis by Levi, et al. evaluated the safety of 
rFVIIa in 35 clinical trials.1  The majority of patients received rFVIIa following spontaneous cerebral 
hemorrhage (31.3%), bleeding from hepatic-induced coagulopathy (27.8%) or trauma (18.7%).  This 
analysis reported a 10% overall incidence of thromboembolic events in the rFVIIa group compared to 
8.7% in patients who received placebo.  The odds ratio for arterial thrombosis was greater than 1 in 
patients older than 65 years, those with spontaneous cerebral hemorrhage, and liver failure (2.43, 1.67, 
2.19, respectively).  There are no reports of thrombosis in three studies evaluating the safety and 
efficacy of PCC use.2,3,8  The absence of thrombosis in published literature should not be considered 
evidence of absence given similar mechanism of action to rFVIIa.  Finally, these marginally efficacious 
agents are expensive: rFVIIa is $2.20/mcg and PCC is $1.32/unit compared to $35/plasma unit.   
Off-label blood factor use has marginal benefit, potential serious adverse effects and high monetary 
cost.  This led the development and implementation of a pharmacist led blood factor stewardship 
program at a tertiary care academic medical hospital.  This study reports the mortality and morbidity 
results of a prospective stewardship program in high-risk patients with an additional goal of cost 
reduction. 
Methods 
Beginning June 2013 all orders for off-label rFVIIa and PCC were prospectively reviewed by a single 
clinical pharmacist. Orders were discussed with the primary team regarding indication, patient specific 
contraindications, appropriate dosing and timing.  Contraindications included: mechanical hardware, DIC 
or thromboembolism within 6 months.  Vascular procedures considered to be high risk warranting blood 
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factor support included: tunneled line placement with INR > 2.5, transjugular liver biopsy with INR > 2, 
right heart catheterization with INR > 1.6, and transjugular intrahepatic portosystemic shunt (TIPS); high 
risk non-vascular procedures included: renal biopsy, biliary interventions, and nephrostomy tube 
placement.  Blood factor support was used in lower risk procedures when clinically indicated.  Blood 
factors for massive transfusion were evaluated for the presence of contraindications and previous blood 
product use.  If contraindications existed, the procedure was not considered high risk, or the use of 
blood factor was deemed to be futile the order was voided.   
The control group was a matched retrospective cohort from June 2012 through May 2013 of all non-
hemophiliac patients who received blood factor at our institution.  The primary endpoint of this study 
was 28-day mortality pre and post stewardship.  Secondary endpoints included: change in INR from 
baseline following first dose of PCC or rFVIIa, adverse events, and units of concurrent blood product 
dispensed.  Twenty-eight-day mortality was evaluated from the last ordered dose in patients with 
multiple orders; multiple orders for the same patient were evaluated separately for secondary 
outcomes.   
 Baseline demographic and clinical characteristics between the two groups were compared using 
the chi-square or Fisher exact test for categorical variables and the Students t test or Mann-Whitney U 
test as appropriate.  Twenty-eight day mortality was analyzed with a logistic regression model which 
included: active bleeding, whether drug use was for a heart catheterization, history of liver failure, 
whether or not drug was administered, factor stewardship implementation date (June 10, 2013).  All 
statistical analyses were performed using SPSS 22 (SPSS, Inc., Chicago, IL).  Statistical significance was set 
at 0.05.  Indiana University institutional review board approval was granted for this study. 
Results 
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From June 2013-May 2014 42 patients had orders for blood factor; 14 did not receive drug due to 
contraindications.  Mean age was 55.4 years (SD +/- 13.3). There were 72 patients in the control group 
from June 2012-May 2013; mean age was 53.7 years (SD +/- 14.8).  In both cohorts there were multiple 
orders per patient: in the pre-implementation group there were 103 orders and post-implementation 
there were 34 orders for 28 patients.  Table 1 describes the past medical history.  The mean baseline PT 
was 28 seconds in both groups.   
Twenty-eight day mortality was equivalent pre and post stewardship for all evaluated patients: 
52.9% (n=70) versus 50% post (n=42), p = 0.77 (Table 2).  Fifty percent of patients died within 28-days 
regardless of receipt of drug in the post-stewardship group.  Evaluation of underlying etiology and 
indication for blood factors by binary logistic regression model demonstrates a significant risk of death 
within 28 days in patients with underlying liver failure (odds ratio, 2.9; 95% confidence interval [CI] 1.8-
7.14) and those with active bleeding (odds ratio, 2.91; 95% CI 1.24-6.88). (Table 3) 
Use of plasma product significantly increased with stewardship implementation: median pre-
intervention was 1 unit versus 4 units administered within 12 hours pre and post-infusion of factor 
product. (p = 0.004), other blood products were not significantly changed (Table 4).   Venous 
thromboembolism (VTE) occurred 2.4% following stewardship implementation compared to none in the 
year prior.  Similarly, DIC occurred 9.5% post-implementation and never before.  The absence of VTE and 
DIC pre-implementation may be attributed to a lack of monitoring or documentation.  Mean change in 
INR pre-stewardship was -0.14 compared to +1.15 in the stewardship group; this is likely due to an 
increase in PCC use which does not affect the INR as strongly as rFVIIa. 
Total rFVIIa use declined with the stewardship; pre-implementation 48.6% (147 mg) of blood factor 
dispensed was rFVIIa, post-implementation this decreased to 16.7% (30 mg) (p < 0.001).  Total dollars 
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dispensed for all blood factors pre-implementation was $505,684, this decreased post-implementation 
to $130,145.30.  Total savings over one year was $375,539. 
Discussion 
The majority of patients in this study had an underlying diagnosis of liver failure.  The use of 
blood factors in patients with liver failure is based on the hypothesis that an elevated PT/INR increases 
the likelihood of bleeding.  However, the PT/INR does not accurately represent the hemostatic status in 
patients with liver failure because increases in von Willebrand and factor VIII and decreases in 
antithrombin and protein C, natural anticoagulants, are not accounted for.9-11 This constellation of 
changes nullifies the accuracy of the PT/INR as a marker of bleeding and literature evaluating the 
bleeding risk during invasive procedures in patients with abnormal coagulation supports the hypothesis 
that cirrhosis patients are at a lower than expected risk of bleeding than the lab values indicate.12 
 While the implementation of the factor stewardship itself did not affect 28-day mortality it is 
noted that factor administration did not improve mortality in a select subgroup of patients; most 
notably, those patients with active hemorrhage (OR 2.91, 95% CI 1.23-6.88) and those bleeding with a 
history of liver disease (OR 2.9, 95% CI 1.8-7.14).  Retrospective studies in patients with active 
hemorrhage due to trauma or hemorrhagic shock have observed decreases in blood product 
administration with factor use, but survival has not been reported.13,14  Kwok et al, evaluated rFVIIa in 
critically ill patients and found that while use as part of a massive transfusion order set inferred a high 
cost, it did not translate into an overall survival benefit.15  It is reasonable to conclude that judicious use 
of factor product in critically ill or trauma patients with active hemorrhage is recommended, but ideal 
factor candidates have not been a concluded from the literature.   
 The role of factor use in hepatic disease has generally evaluated surrogate endpoints such as PT 
goals and blood product administration with limited reports on survival.16  Bendtsen et al, conducted a 
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meta-analysis (n=497) of acute variceal bleeding in patients with end stage liver disease receiving rFVIIa 
or placebo.17  While factor administration did decrease the recurrence of bleeding within five days of 
administration it did not affect the five day or 40-day survival of patients.  Similarly, our study did not 
demonstrate a long term benefit of factor administration in patients with liver failure with active 
hemorrhage leading us to conclude previously evaluated surrogate markers are inappropriate given the 
risk benefit ratio of factor products.   
 This study included a small number of patients with a variety of indications.  Additionally, 
multiple patients in both cohorts received more than one dose of blood factor which makes it difficult to 
assess the underlying coagulopathy at the time of administration and the effect with regards to 
mortality.  Other limitations include: a lack of monitoring for DIC in the pre-stewardship group which 
contributed to a significant finding of DIC at baseline in the post-implementation group; and the 
retrospective nature of the study may have contributed to a decreased identification of 
thromboembolism following blood factor use. 
While the role of stewardship has been widely published and recommended for developing and 
instituting antimicrobials there is limited data and recommendations in other areas of medication use.18  
As inferred by common practice the utilization of order sets may help to curb or limit prescribing habits, 
but this may not be applicable in real time urgent or critical situations.  In this regard the authors would 
like to convey the importance of a stewardship program that allows real time discussion with clinicians 
rather than medication reviews as a systematic process.  In these acute situations where costly 
medications with a narrow risk benefit profile have the potential for treating complications it is 
necessary for real time patient assessment and health care provider dialogue.  
Conclusion 
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Although no difference was observed in 28 day mortality among patients receiving rFVIIa pre or 
post implementation of a pharmacy stewardship, this study highlights that in routine clinical practice the 
futility and potential misuse of high-risk, expensive drugs can be controlled.  Patient characteristics and 
rationale for use may vary from institution to institution and the implementation of stewardship should 
be considered if excess or misuse of rFVIIa is observed.  Implementation with a dedicated trained 
hematology pharmacist is reasonable, similar to the process of having a trained dedicated pharmacist 
for antimicrobial stewardship.  
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Table 1. Baseline Characteristics 
Past Medical History 
Characteristic, n (%) June 2012-May 2013 
N=70 
June 2013-May 2014 
N=42 
P value 
Past Medical History   0.125 
Chronic liver failure 48 (68) 30 (71.4)  
Unknown coagulopathy 3 (4.3) 0  
Acute/reversible liver failure 8 (11.4) 1 (2.4)  
Elevated INR/Bleeding from vitamin K 
antagonism 
2 (2.9) 2 (4.8)  
Cancer related liver failure 4 (5.7) 1 (2.4)  
Other 5 (7.1) 8 (19)  
Indication   0.515 
Bleeding 35 (50) 19 (45.2)  
Prior to heart catheterization 7 (10) 7 (16.7)  
Prior to other procedure 23 (32.9) 11 (26.2)  
Reversal of vitamin K antagonism 1 (1.4) 2 (4.8)  
Factor VII deficiency 0 1 (2.4)  
Elevated INR without evidence of 
bleeding 
4 (5.7) 2 (4.8)  
Age years, mean 53.8 (+/- 12) 55.4 (+/- 13) 0.362 
Vitamin K administered concurrently 48 (46.6) 25 (73.5) 0.006 
Baseline PT, mean 28.7 (+/- 19.3) 28.2 (+/- 11.4) 0.13 
DIC present at baseline 24 (23.3) 16 (47.1) 0.018 
 
Table 2 
28-day mortality 
 June 2012 – May 2013 
N = 70 
June 2013 – May 2014 
N = 42 
P value 
Intention to prescribe, % 52.9 50 0.086 
 Received drug 
N = 28 
Did not receive drug 
N = 14  
 
June 2013 – May 2014 
Receipt of drug, % 
50 50 1 
 
Table 3 
Binary logistic regression model 
 
Characteristic 
28-day mortality odds ratio 
(95% confidence interval) 
Pre-implementation vs. post-implementation 1.14 (0.42-3.09) 
Receipt of drug 1.43 (0.33-6.17) 
History of liver failure 2.9 (1.18-7.14) 
Heart Catheterization 0.14 (0.02-0.76) 
Active bleeding 2.91 (1.24-6.88) 
 
Table 4 
Secondary outcomes 
 June 2012 – May 2013 June 2013 – May 2014 P value 
INR change, mean -0.14 +1.15   
Packed red blood cells, 
units mean 
2.8 6.4 0.047 
Platelets, units mean 1 1.5 0.165 
Plasma, units median 1 4 0.004 
Cryoprecipitate, units mean 0 1.8 0.046 
 
